Cancer Medicine最新文献

{"title":"Nationwide Genomic Data Analysis of Japanese Prostate Cancer Patients From C-CAT Database","authors":"Shigehiro Tsukahara,&nbsp;Masaki Shiota,&nbsp;Shohei Nagakawa,&nbsp;Tokiyoshi Tanegashima,&nbsp;Satoshi Kobayashi,&nbsp;Takashi Matsumoto,&nbsp;Masatoshi Eto","doi":"10.1002/cam4.71085","DOIUrl":"https://doi.org/10.1002/cam4.71085","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>Prostate cancer is a leading malignancy among men, and genomic alterations are known to impact disease progression and treatment response. However, racial and ethnic differences may influence genomic profiles, necessitating population-specific analyses. This study aimed to characterize the genomic landscape and its clinical significance in Japanese patients with treatment-resistant, unresectable prostate cancer using data from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analyzed data from patients with advanced or metastatic prostate cancer who had progressed after standard therapies and underwent comprehensive genomic profiling between 2019 and 2022. We assessed the frequency of genomic alterations, tumor mutation burden (TMB), and microsatellite instability (MSI) status. Associations between genomic features and clinical outcomes were also examined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 2634 patients were included. Family history was reported in 12.5% for prostate cancer, 1.5% for breast cancer, 5.2% for pancreatic cancer, and 1.1% for ovarian cancer. <i>AR</i> gene alterations were observed in 18% of patients. <i>TP53</i> and <i>BRCA2</i> mutations were identified in 34% and 12% of cases, respectively. Mutations in <i>TP53</i>, as well as alterations in genes related to the cell cycle, epigenetic regulation, MYC signaling, and the PI3K pathway, were associated with poorer overall survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study provides a comprehensive overview of genomic alterations in advanced prostate cancer among Japanese patients and identifies key mutations linked to prognosis. These findings highlight the value of personalized prognostic assessment based on genomic profiling to guide clinical decision-making in this population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 15","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71085","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144705381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C-Reactive Protein to Lymphocyte Ratio (CLR) and Lactate Dehydrogenase to Albumin Ratio (LAR) as Prognostic Biomarkers in Acral Melanoma: Association With Tertiary Lymphoid Structures and Immune Cell Infiltration","authors":"Donglin Kang,&nbsp;Xinyu Su,&nbsp;Jiayu Wang,&nbsp;Lianjun Zhao,&nbsp;Rong Huang,&nbsp;Zhengyun Zou","doi":"10.1002/cam4.71078","DOIUrl":"https://doi.org/10.1002/cam4.71078","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To investigate the correlation between peripheral blood CRP-to-lymphocyte ratio (CLR) and lactate dehydrogenase-to-albumin ratio (LAR) levels, prognosis, and the tumor microenvironment (TME) in patients with acral melanoma (AM), with a focus on tertiary lymphoid structures (TLS) and immune cell infiltration.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective cohort of 36 patients with acral melanoma was included. Clinical data and hematological parameters were collected. The maturity of TLS, the proportion of immune cells, and their spatial distribution within the TME were assessed using H&amp;E staining and multiplex immunofluorescence. Kaplan–Meier survival curves and Cox regression models were employed to examine the association between these indicators and patient survival. Non-parametric tests and Spearman's correlation analysis were used to compare CLR and LAR levels across patients with different TLS maturity and immune infiltration statuses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Elevated levels of CLR and LAR in the blood are associated with poorer prognosis in patients with acral melanoma. The levels of CLR and LAR vary across patients with TLS of different maturities, and these levels decrease as TLS maturity increases. Additionally, CLR and LAR levels are significantly correlated with the proportions of CD4+ and CD8+ T cells in TME, with higher levels of CLR and LAR being linked to reduced immune cell infiltration.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Elevated CLR and LAR levels are associated with poorer prognosis in AM patients, and this relationship is closely linked to the maturity of TLS and the extent of immune cell infiltration within the TME.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 15","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71078","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144705380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Data-Driven Epigenetic Characterization of Morning Fatigue Severity in Oncology Patients Receiving Chemotherapy: Associations With Epigenetic Age Acceleration, Blood Cell Types, and Expression-Associated Methylation","authors":"Caroline Le,&nbsp;Maureen Lewis,&nbsp;Carolyn S. Harris,&nbsp;Liam Berger,&nbsp;Esther Chavez-Iglesias,&nbsp;Lisa Morse,&nbsp;Anatol Sucher,&nbsp;Ritu Roy,&nbsp;Adam Olshen,&nbsp;Marilyn J. Hammer,&nbsp;Steve Paul,&nbsp;Margaret Wallhagen,&nbsp;Raymond Chan,&nbsp;Michael Sayer,&nbsp;Sue Yom,&nbsp;Nam-Woo Cho,&nbsp;Alexandre Chan,&nbsp;Jon Levine,&nbsp;Anand Dhruva,&nbsp;Christine Miaskowski,&nbsp;Yvette P. Conley,&nbsp;Kord M. Kober","doi":"10.1002/cam4.71067","DOIUrl":"https://doi.org/10.1002/cam4.71067","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Moderate-to-severe fatigue commonly occurs in patients with cancer. Given the numerous roles that epigenetic processes may play in the development and severity of fatigue, the purposes of this study were to (1) use a data-driven discovery approach to evaluate for mechanisms underlying morning fatigue in a group of oncology patients receiving chemotherapy and (2) identify common biological mechanisms associated with morning fatigue severity across these independent epigenetic evaluations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients completed questionnaires during the week prior to their chemotherapy treatment. Severity of morning fatigue was evaluated using the Lee Fatigue Scale. Associations between morning fatigue severity and epigenetic aging acceleration (EAA), immune cell type compositions, and differential methylation of expression-associated loci (eCpGs) in distal regions (i.e., upstream of a gene on the same chromosome) were evaluated. These results were then evaluated for common biological mechanisms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>High morning fatigue was associated with older epigenetic age, positive EAA, and higher levels of EAA. Patients of the “Fast ager” type were more likely to have high morning fatigue. Higher morning fatigue was associated with lower (CD4 memory, CD8 memory, and NK) and higher (neutrophil and T regulatory) estimated proportions of cell types. Morning fatigue severity was associated with one differentially methylated distal region containing five eCpGs mapping to three genes (i.e., CILP, ONECUT1, SLCO3A1). Preliminary support was found for the role of Inflammaging as a common biological mechanism for morning fatigue.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study provides an epigenetic characterization of morning fatigue in patients receiving chemotherapy. The findings suggest that biological aging, gene regulatory, and inflammatory processes may contribute to morning fatigue and provide future targets for therapeutic interventions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 15","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71067","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144695757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Photodynamic Therapy and Dietary Antioxidants: A Dual Strategy for Genome Stability and DNA Damage Repair","authors":"J. P. Jose Merlin,&nbsp;Sheeja S. Rajan,&nbsp;Heidi Abrahamse","doi":"10.1002/cam4.71032","DOIUrl":"https://doi.org/10.1002/cam4.71032","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Photodynamic therapy (PDT) is an emerging cancer treatment that relies on photosensitizers (PS) activated by specific light wavelengths to produce reactive oxygen species (ROS), effectively targeting malignant cells. However, ROS can also harm surrounding healthy tissues, necessitating strategies to reduce unintended DNA damage. Recent attention has turned to dietary antioxidants as potential agents to protect genome integrity and enhance DNA repair mechanisms during PDT.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recent Advances</h3>\u0000 \u0000 <p>This review explores the complementary roles of PDT and dietary antioxidants in modulating oxidative stress and DNA repair pathways. Key DNA repair systems such as base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), homologous recombination (HR), and non-homologous end joining (NHEJ) are discussed in the context of their response to PDT-induced damage. The regulatory role of dietary compounds such as vitamins, polyphenols, flavonoids, phenolic acids, and alkaloids are also examined. Evidence suggests that specific dietary antioxidants can reduce ROS-induced genomic instability by enhancing the efficiency of DNA repair pathways and modulating gene expression related to repair mechanisms. The combination of PDT with antioxidant intake might reduce mutation risk in healthy cells while preserving the cellular toxicity on cancerous tissue.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Integrating dietary antioxidants with PDT offers a promising dual strategy maximizing tumor destruction while protecting normal cells through enhanced genome maintenance. Continued investigation is necessary to improve this synergistic approach and develop targeted protocols for clinical application, with the aim of enhancing therapeutic outcomes and patient safety.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 15","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71032","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144695811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Socioeconomic Status on Financial Toxicity: The Chain Mediating Roles of Social Support and Self-Efficacy","authors":"Yan Liu,&nbsp;Pengfei Li,&nbsp;Boyu Liu,&nbsp;Yuantao Qi,&nbsp;Weimin Guan,&nbsp;Nan Zhang,&nbsp;Youhua Lu","doi":"10.1002/cam4.71083","DOIUrl":"https://doi.org/10.1002/cam4.71083","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Cancer patients experience severe financial toxicity, with the mechanisms influencing the relationship between socioeconomic status and financial toxicity in lung cancer patients remaining poorly defined. This study aims to investigate how social support and self-efficacy mediate the association between socioeconomic status and financial toxicity among lung cancer patients in China.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A survey of 755 lung cancer patients was conducted at a tertiary oncology hospital in Shandong Province, China, from October to December 2023, utilizing random sampling. Data collection included demographic and socioeconomic details, along with assessments of social support, self-efficacy, and financial toxicity. Regression and Bootstrap analyses were used to explore the sequential mediating effects of socioeconomic status, self-efficacy, social support, and financial toxicity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>(1) Significant correlations emerged among socioeconomic status, social support, self-efficacy, and financial toxicity (<i>p</i> &lt; 0.05). (2) Socioeconomic status was significantly associated with financial toxicity (<i>p</i> &lt; 0.05). (3) Self-efficacy mediated the relationship between socioeconomic status and financial toxicity (<i>β</i> = 0.203, <i>p</i> &lt; 0.05), whereas social support did not exhibit a mediating effect in this relationship (<i>β</i> = 0.039, <i>p</i> = 0.194). (4) Social support and self-efficacy had a chain-mediated role in the relationship between socioeconomic status and financial toxicity in patients with multimorbidity (<i>β</i> = 0.072, <i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study identifies social support and self-efficacy as chained mediators that link socioeconomic status with financial toxicity among lung cancer patients. It is recommended that targeted interventions be implemented to increase social support for patients with lower socioeconomic status to mitigate financial toxicity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 15","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71083","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144695756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse Physical Health Outcomes and Healthcare Service Utilization in Siblings of Children With Cancer: A Systematic Review","authors":"Victorine Sirveaux,&nbsp;Lily Puterman-Salzman,&nbsp;Yue Qian Zhang,&nbsp;Eleni Sotirakos,&nbsp;Philippe Dodin,&nbsp;Guillaume Dumas,&nbsp;Eyal Cohen,&nbsp;Nadia Roumeliotis,&nbsp;Petros Pechlivanoglou,&nbsp;Hallie Coltin","doi":"10.1002/cam4.71035","DOIUrl":"https://doi.org/10.1002/cam4.71035","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Siblings of children with cancer may be vulnerable to compromised long-term health. We aimed to describe the frequency (prevalence, incidence) of adverse physical health outcomes and healthcare service utilization among siblings of children with cancer and compare the risk of the above outcomes to siblings of children without cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We searched Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials, CINAHL, and Clarivate Web of Science through June 15, 2024. We included English and French-language studies, both with and without a healthy control population, that reported adverse physical health outcomes and/or healthcare service utilization outcomes among siblings of children with cancer. Studies focusing exclusively on mental health or quality of life were excluded. Abstracts were screened by two reviewers; full-text articles underwent data abstraction and risk of bias assessment. Results were synthesized descriptively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 26,570 studies screened, 44 were included. Heterogeneity was observed in all reported outcomes: mortality; cancer; organ system disease; overweight/obesity; pain; congenital anomalies; comorbidities; infections; amputations; adverse health behavior (smoking, alcohol consumption); infertility; healthcare service utilization (hospitalization, emergency department/urgent care visits, prescriptions). We detected a trend toward increased risk of cancer, hospitalizations, and prescription medication use compared to control siblings. Significant study heterogeneity rendered meta-analyses inappropriate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Siblings of children with cancer are likely vulnerable to various adverse health outcomes. However, the published literature is widely heterogeneous regarding study design, populations, and outcomes measurements, limiting our comprehensive analysis of risk. Future research with homogenized methodology is needed to better quantify risk, which would inform targeted surveillance guidelines and interventions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 15","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144695812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Survival Analysis of Neoadjuvant Chemoradiotherapy Versus Adjuvant Chemoradiotherapy for Locally Advanced Low Rectal Cancer","authors":"Siyuan Chen,&nbsp;Ruiyan Wu,&nbsp;Juefeng Wan,&nbsp;Yun Xu,&nbsp;Yaqi Wang,&nbsp;Zhiyuan Zhang,&nbsp;Lili Huang,&nbsp;Yujun Liu,&nbsp;Yingxuan Lin,&nbsp;Luoxi He,&nbsp;Yun Deng,&nbsp;Fan Xia,&nbsp;Ye Xu,&nbsp;Zhen Zhang,&nbsp;Hongtu Zheng","doi":"10.1002/cam4.71042","DOIUrl":"https://doi.org/10.1002/cam4.71042","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>To compare the long-term survival of patients with locally advanced low rectal cancer (LALRC), receiving neoadjuvant chemoradiotherapy (NCRT) versus adjuvant chemoradiotherapy (ACRT).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Materials</h3>\u0000 \u0000 <p>This retrospective observational study included 1169 patients with LALRC (Stage II/III disease located ≤ 5 cm from the anal verge) who underwent diagnosis and treatment at Fudan University Shanghai Cancer Center from February 2006 to March 2021. In Stage II/III low rectal cancer patients, one-to-one matched pairs were created from the ACRT and NCRT groups using propensity score matching (PSM) based on baseline characteristics. OS and DFS were evaluated using the Kaplan–Meier method alongside the univariate Cox regression model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In Stage II patients, 65 received ACRT and 107 received NCRT. For Stage III, 282 received ACRT and 715 received NCRT. After PSM, 45 paired Stage II patients and 243 paired Stage III patients were selected. In Stage II patients, there was no significant difference in OS and DFS between the groups. For Stage III, the 5- and 10-year OS rates were 79.61% and 77.67% in the NCRT group, compared to 61.08% and 44.57% in the ACRT group (<i>p</i> &lt; 0.001). The 5- and 10-year DFS rates were 69.93% and 65.26% in the NCRT group, versus 48.07% and 40.77% in the ACRT group (<i>p</i> &lt; 0.001). Additionally, in Stage III patients, NCRT was associated with a significant reduction in the risk of death and recurrence compared to ACRT (OS: HR = 0.47, <i>p</i> = 0.0001; DFS: HR = 0.55, <i>p</i> = 0.0001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>For patients with Stage III low rectal cancer, NCRT significantly improved the long-term DFS rate and OS rate, in comparison to adjuvant chemoradiotherapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 15","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71042","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144695929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Angiogenic Agents for Advanced Hepatocellular Carcinoma Induce Liver Atrophy","authors":"Taijiro Wake,&nbsp;Tomoharu Yamada,&nbsp;Ryosuke Tateishi,&nbsp;Makoto Moriyama,&nbsp;Yuki Matsushita,&nbsp;Kazuya Okushin,&nbsp;Takuma Nakatsuka,&nbsp;Masaya Sato,&nbsp;Tatsuya Minami,&nbsp;Yotaro Kudo,&nbsp;Mitsuhiro Fujishiro","doi":"10.1002/cam4.71066","DOIUrl":"https://doi.org/10.1002/cam4.71066","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Systemic therapy for advanced hepatocellular carcinoma (HCC) includes multi-kinase inhibitors with anti-vascular endothelial growth factor (VEGF) activity and anti-VEGF monoclonal antibodies in combination with immune checkpoint inhibitors. This study aimed to investigate and compare the chronological changes in liver volume between patients who received atezolizumab plus bevacizumab (Atezo/Bev) and those who received lenvatinib.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We enrolled patients who received initial treatment with either Atezo/Bev or lenvatinib for advanced HCC between October 2018 and May 2023. Patients underwent periodic computed tomography (CT) or magnetic resonance imaging (MRI) to evaluate systemic therapy effects. Patients with portal vein thrombosis or prior liver resection/transplantation were excluded. Liver volume was measured at baseline and at 8 and 16 weeks after the initiation of treatment using commercially available software. Liver volume at each time point was expressed as a proportion relative to baseline. A linear regression analysis was used to analyze the chronological changes in liver volume.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventy-three patients (40 in the Atezo/Bev group and 33 in the lenvatinib group) were included in this retrospective study. Liver volume decreased in 54 patients (74%) at week 8; the average volume relative to baseline was 0.92 (95% confidence interval: 0.90–0.94, <i>p</i> &lt; 0.01). Liver volume decreased in patients with both shrinking and enlarged tumors. Multivariate analysis indicates that the decrease in nontumoral liver volume was more significant in the lenvatinib group than in the Atezo/Bev group (<i>p</i> = 0.04).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Anti-angiogenic therapy for advanced HCC can lead to liver atrophy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 15","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71066","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144695715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Sleep in Pediatric Cancer: A Scoping Review of Assessment Tools for Quality and Care","authors":"Elena Rostagno,&nbsp;Veronica Rivi,&nbsp;Pierfrancesco Sarti,&nbsp;Pietro Guastella,&nbsp;Dorella Scarponi,&nbsp;Johanna Maria Catharina Blom","doi":"10.1002/cam4.71051","DOIUrl":"https://doi.org/10.1002/cam4.71051","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Pediatric cancer patients experience unique and multifaceted sleep disturbances due to the disease, treatment regimens, and the hospital environment. These disruptions can detrimentally impact neurocognitive functioning, emotional well-being, and overall quality of life, making accurate sleep assessment critical yet challenging in this population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To examine and evaluate the current tools used to assess sleep quality in pediatric oncology patients, with a focus on their reliability, feasibility, and relevance to clinical and research settings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A scoping review methodology was employed to identify and synthesize studies using various sleep assessment tools in pediatric cancer populations. Tools reviewed included actigraphy, sleep diaries, validated sleep scales, and polysomnography. Studies were analyzed for general reliability, feasibility in clinical and research contexts, and applicability to pediatric oncology-specific concerns.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The review found that while actigraphy and sleep diaries are frequently used because of their noninvasive nature and relative ease of implementation, limitations exist in terms of consistency and interpretability. Sleep scales varied in their psychometric properties and relevance across age groups and treatment phases. Polysomnography, though considered the gold standard, was less feasible in routine clinical settings because of its complexity and cost. Across tools, variability was observed in the alignment between measured parameters and clinically relevant sleep issues in pediatric cancer patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A wide range of tools exists for assessing sleep in pediatric oncology, each with distinct strengths and limitations. Selection of the most appropriate tool should consider the specific sleep concern, patient age, clinical context, and resource availability. This review provides a framework for clinicians and researchers to make informed choices, encouraging thoughtful integration of sleep assessments into both practice and study design.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 14","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71051","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144681326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Nanoparticle-Mediated Cuproptosis and Photodynamic Synergistic Strategy: A Novel Horizon for Cancer Therapy”","authors":"","doi":"10.1002/cam4.71022","DOIUrl":"https://doi.org/10.1002/cam4.71022","url":null,"abstract":"<p>Zhang, J., Zhang, A., Guo, Y., Miao, G., Liang, S., Wang, J. and Wang, J. (2025), Nanoparticle-Mediated Cuproptosis and Photodynamic Synergistic Strategy: A Novel Horizon for Cancer Therapy. Cancer Med, 14: e70599. https://doi.org/10.1002/cam4.70599.</p><p>In the corresponding author section, the positions of the two corresponding authors are reversed. Wang Junhong is designated as the first corresponding author, while Wang Jie is listed as the second corresponding author. This article is free from any conflicts of interest, and all co-authors have consented to the modification of the corresponding author sequence.</p><p>We apologize for this error.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 14","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}